Nancy Lelicoff Joins as Executive Vice President of Regulatory, Quality Assurance and Clinical Affairs Global molecular diagnostics innovator,Sense Biodetection (Sense), today announced the appointment
Marty Rochesterâs March 24 opinion piece, âOy vey: The excesses of identity politics,â cries out for rebuttal on a number of fronts. Since Iâm having trouble deciding whether I am, in Rochesterâs words, a âgarden-variety liberalâ or a âleft-wing extremist,â Iâll let other more astute readers…
Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort
Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time
TEL AVIV, Israel & MELBOURNE, Australia (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significant improvements in multiple measures of Meibomian gland secretion and patients’ ability to wear contact lenses as desired. Full data from the study will be submitted for presentation at an upcoming scientific meeting